Tyra Bioscience (TYRA) AI Stock Analysis

• Market Cap: $691.26M
• Dividend Yield: N/A
• Average Volume (3M): 224.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: N/A
• EPS Growth: -5.63%
• Country: US
• Employees: 60
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 53,297,140
• 10 Day Avg. Volume: 197,042
• 30 Day Avg. Volume: 224,212
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: 563.82
• Enterprise Value/Gross Profit: -14.72K
• Enterprise Value/Ebitda: -2.31
• 1Y Price Target: $32.40
• Price Target Upside: 149.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 41 Neutral
• Price Target: ―

Tyra Bioscience's overall stock score reflects its high-risk profile typical for early-stage biotechnology firms. While the company demonstrates strong liquidity, its lack of revenue and increasing operational losses highlight financial challenges. Technical indicators show positive momentum, but the high valuation risk due to negative earnings limits the score. Investors should be cautious, considering both the potential for significant growth and the inherent risks.

Positive Factors

Strong Liquidity

Strong liquidity provides Tyra Bioscience with the financial flexibility to continue its R&D efforts without immediate revenue, supporting long-term growth.

Innovative Pipeline

The development of innovative therapies like dabogratinib positions Tyra Bioscience as a leader in precision medicine, enhancing its competitive edge in oncology.

Strategic Partnerships

Strategic partnerships provide Tyra with essential funding and resources, enabling sustained R&D and potential revenue streams from successful collaborations.

Negative Factors

Increasing Operational Losses

Rising operational losses highlight financial challenges, potentially straining resources and necessitating further external financing to sustain operations.

Reliance on External Financing

Dependence on external funding can limit financial autonomy and increase vulnerability to market conditions, impacting long-term sustainability.

Zero Revenue

The absence of revenue underscores the company's developmental stage, posing risks to cash flow and necessitating successful product commercialization.

Tyra Bioscience Business Overview & Revenue Model

Company Description

Tyra Bioscience (TYRA) is a biotechnology company focused on developing targeted therapies for cancer treatment. The company operates within the life sciences sector, specializing in precision medicine aimed at addressing oncogenic mutations. Tyra Bioscience's core product pipeline includes small molecule inhibitors designed to target specific genetic alterations in cancer cells, enhancing treatment efficacy and reducing side effects.

How the Company Makes Money

Tyra Bioscience makes money primarily through its research and development activities in oncology therapeutics, which are aimed at bringing novel cancer treatments to market. The company generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on product sales if the drugs are successfully commercialized. Additionally, Tyra Bioscience may secure funding through grants and government programs focused on advancing cancer research. As its drugs progress through clinical trials and potentially receive regulatory approval, the company could also earn revenue from direct sales or licensing agreements.

Tyra Bioscience Financial Statement Overview

Summary

Tyra Bioscience's financials reflect its focus on research and development in the biotechnology sector. The lack of revenue and increasing losses are typical of a company investing heavily in future growth. While the company maintains strong liquidity through cash reserves, its reliance on external financing and negative profit margins indicate a high-risk profile. Investors should monitor the company's progress towards revenue generation and cost management to assess future financial health.

Income Statement

Tyra Bioscience has consistently reported zero revenue, which is typical for early-stage biotechnology firms focusing on research and development. The company shows increasing losses over the years, with a notable rise in EBIT and net losses, indicating higher operational expenses. This results in negative profit margins, reflecting the company's developmental stage and need for capital investment.

Balance Sheet

The balance sheet shows strong liquidity with significant cash and short-term investments, outpacing total debt, resulting in negative net debt. The equity ratio is robust, showing a high proportion of assets financed by equity, which is positive for stability. However, the company's negative stockholders' equity in previous years reflects accumulated losses, posing a potential risk.

Cash Flow

Cash flow analysis reveals negative operating cash flow, typical for a company in the R&D phase. The high free cash flow outflow, though concerning, is offset by strong financing cash flow, suggesting reliance on external funding. The absence of revenue growth limits free cash flow growth, highlighting reliance on external capital to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	496.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-19.00K	-519.00K	-353.00K	-296.00K	-140.00K	-47.00K
EBITDA	-121.10M	-85.96M	-79.59M	-58.63M	-26.15M	-9.25M
Net Income	-105.83M	-86.48M	-69.13M	-51.72M	-26.14M	-9.31M
Balance Sheet
Total Assets	321.50M	363.56M	225.86M	266.18M	306.70M	16.01M
Cash, Cash Equivalents and Short-Term Investments	296.27M	341.44M	203.47M	251.21M	302.18M	15.22M
Total Debt	6.02M	6.22M	6.50M	2.62M	1.18M	142.00K
Total Liabilities	19.35M	20.41M	21.59M	8.35M	4.96M	29.65M
Stockholders Equity	302.15M	343.15M	204.26M	-95.70M	301.74M	-13.64M
Cash Flow
Free Cash Flow	-86.73M	-70.44M	-50.91M	-50.84M	-24.41M	-8.07M
Operating Cash Flow	-86.63M	-69.77M	-50.14M	-50.28M	-23.75M	-7.76M
Investing Cash Flow	81.41M	-98.40M	-144.60M	-559.00K	-645.00K	-312.00K
Financing Cash Flow	4.22M	202.14M	1.54M	632.00	311.35M	23.43M

Tyra Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Positive. The current price of 12.97 is above the 20-day moving average (MA) of 12.46, above the 50-day MA of 11.59, and above the 200-day MA of 11.52, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 59.86 is Neutral, neither overbought nor oversold. The STOCH value of 43.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TYRA.

Tyra Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	72 Outperform	651.88M	51.23	2.66%	―	85820.30%	―
TBPH	66 Neutral	708.58M	60.15	5.80%	―	24.49%	―
SAGE	54 Neutral	543.61M	-1.77	-81.68%	―	-27.59%	34.00%
MGTX	41 Neutral	658.06M	-4.01	-5321.11%	―	366.84%	-35.87%
TYRA	41 Neutral	$691.26M	―	-31.21%	―	―	-5.63%
MNMD	40 Neutral	811.86M	-7.29	―	―	―	39.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Tyra Bioscience Corporate Events

Tyra Biosciences Appoints Adele M. Gulfo to Board

Tyra Biosciences announced changes in its Board of Directors on January 28, 2025, with the resignation of Nina Kjellson and the appointment of Adele M. Gulfo. Gulfo brings extensive experience from her roles in major pharmaceutical companies like Sumitomo Pharma America, Mylan, and Pfizer. Her appointment is expected to strengthen Tyra Biosciences’ strategic direction, given her background in commercial and business development in the biopharmaceutical industry. With her appointment, Gulfo will also receive stock options and cash compensation under the company’s director compensation program.